Comgest Global Investors S.A.S. purchased a new stake in shares of Nevro Corp (NYSE:NVRO) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 39,400 shares of the medical equipment provider’s stock, valued at approximately $2,720,000. Comgest Global Investors S.A.S. owned 0.13% of Nevro as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Hershey Trust Co. bought a new position in shares of Nevro in the fourth quarter worth approximately $119,000. Public Employees Retirement Association of Colorado bought a new position in shares of Nevro in the fourth quarter worth approximately $160,000. Ameritas Investment Partners Inc. increased its position in shares of Nevro by 17.3% in the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after purchasing an additional 358 shares during the last quarter. PNC Financial Services Group Inc. bought a new position in shares of Nevro in the second quarter worth approximately $190,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Nevro in the third quarter worth approximately $211,000.
Nevro Corp (NYSE:NVRO) opened at $80.10 on Tuesday. Nevro Corp has a 52-week low of $65.00 and a 52-week high of $99.63. The company has a quick ratio of 6.81, a current ratio of 8.78 and a debt-to-equity ratio of 0.59.
Several research analysts recently weighed in on NVRO shares. Northland Securities restated a “buy” rating and issued a $96.00 price objective on shares of Nevro in a research report on Tuesday, November 7th. BidaskClub cut shares of Nevro from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. ValuEngine cut shares of Nevro from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Canaccord Genuity decreased their price objective on shares of Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, November 7th. Finally, TheStreet upgraded shares of Nevro from a “d+” rating to a “c-” rating in a research report on Monday, November 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Nevro presently has a consensus rating of “Hold” and an average price target of $99.25.
TRADEMARK VIOLATION NOTICE: “Comgest Global Investors S.A.S. Invests $2.72 Million in Nevro Corp (NVRO)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/20/comgest-global-investors-s-a-s-invests-2-72-million-in-nevro-corp-nvro.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp (NYSE:NVRO).
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.